Projects per year
Wegener's granulomatosis (WG) is a chronic, relapsing, systemic autoimmune disease. Rituximab, a monoclonal antibody against human CD20, has shown promise as a novel treatment for WG. The monitoring of therapeutic B-cell 'depletion' by peripheral blood flow cytometry has been proposed to help monitor rituximab therapy. We report the case of a patient with known WG and granulomatous disease, successfully treated with rituximab, who relapsed whilst peripheral blood monitoring apparently indicated persistent B-cell depletion. Further investigations demonstrated CD20(+) B cells in tissue at sites of active disease. The implications for disease pathogenesis and clinical monitoring of disease are discussed.
|Number of pages||3|
|Journal||Nephrology, Dialysis, Transplantation|
|Publication status||Published - 1 Sept 2008|
- B-cell depletion
FingerprintDive into the research topics of 'Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood'. Together they form a unique fingerprint.
- 1 Finished
Probing the Unexpected Sensitivity of Autoantibody Production to Anti-B Cell Therapy with Rituximab Anti-CD20 Antibody
Savage, C. & MacLennan, I.
12/09/05 → 11/09/08
Project: Research Councils